BrightSpring Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for BrightSpring Health (BTSG).

Price Target Range — 11 Quarters

Analyst Consensus — 19 Analysts

1S.Buy

17Buy

1Hold

Consensus RatingBuy# Analysts19Avg. Consensus PT$54Upside to Avg. PT-10.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 13, 2026	BTIG	David Larsen	Maintained	Buy	$90
Aug 3, 2026	BTIG	David Larsen	Maintained	Buy	$90
Jul 14, 2026	Morgan Stanley	Erin Wright	PT Raise	Overweight	$71→$80
Jul 14, 2026	Keybanc	Matthew Gillmor	PT Raise	Overweight	$60→$80
Jul 13, 2026	Wells Fargo	Stephen Baxter	PT Raise	Overweight	$61→$78
Jul 13, 2026	Guggenheim	Jason Cassorla	Initiate	Buy	$81
Jul 10, 2026	Raymond James	Parker Snure	Initiate	Outperform	$80
Jul 8, 2026	UBS	A.J. Rice	PT Raise	Buy	$63→$85
Jul 2, 2026	B of A Securities	Kevin Fischbeck	PT Raise	Buy	$66→$77
Jun 22, 2026	BTIG	David Larsen	PT Raise	Buy	$65→$90
Jun 18, 2026	TD Cowen	Charles Rhyee	PT Raise	Buy	$65→$81
Jun 8, 2026	Goldman Sachs	Scott Fidel	Initiate	Buy	$71
Jun 2, 2026	Morgan Stanley	Erin Wright	PT Raise	Overweight	$62→$71
May 6, 2026	Morgan Stanley	Erin Wright	PT Raise	Overweight	$48→$62
May 5, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$52→$61
May 4, 2026	Wells Fargo	Stephen Baxter	PT Raise	Overweight	$50→$61
May 4, 2026	TD Cowen	Charles Rhyee	PT Raise	Buy	$60→$65
May 4, 2026	Keybanc	Matthew Gillmor	PT Raise	Overweight	$55→$60
May 4, 2026	Stephens & Co.	Raj Kumar	PT Raise	Overweight	$53→$64
May 4, 2026	BMO Capital	Sean Dodge	PT Raise	Outperform	$52→$60

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

BTIG analyst David Larsen reiterates BrightSpring Health (NASDAQ:BTSG) with a Buy and maintains $90 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

BTIG analyst David Larsen reiterates BrightSpring Health (NASDAQ:BTSG) with a Buy and maintains $90 price target.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on BrightSpring Health, Raises Price Target to $80

Morgan Stanley analyst Erin Wright maintains BrightSpring Health (NASDAQ:BTSG) with a Overweight and raises the price target from $71 to $80.

Benzinga Newsdesk

PRO
Keybanc Maintains Overweight on BrightSpring Health, Raises Price Target to $80

Keybanc analyst Matthew Gillmor maintains BrightSpring Health (NASDAQ:BTSG) with a Overweight and raises the price target from $60 to $80.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on BrightSpring Health, Raises Price Target to $78

Wells Fargo analyst Stephen Baxter maintains BrightSpring Health (NASDAQ:BTSG) with a Overweight and raises the price target from $61 to $78.

Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On BrightSpring Health with Buy Rating, Announces Price Target of $81

Guggenheim analyst Jason Cassorla initiates coverage on BrightSpring Health (NASDAQ:BTSG) with a Buy rating and announces Price Target of $81.

Benzinga Newsdesk

BrightSpring Health Services Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

BrightSpring Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

PRO
BTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

PRO
Morgan Stanley Maintains Overweight on BrightSpring Health, Raises Price Target to $80

PRO
Keybanc Maintains Overweight on BrightSpring Health, Raises Price Target to $80

PRO
Wells Fargo Maintains Overweight on BrightSpring Health, Raises Price Target to $78

PRO
Guggenheim Initiates Coverage On BrightSpring Health with Buy Rating, Announces Price Target of $81

People Also Watch

People Also Watch

BrightSpring Health Services Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

BrightSpring Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

PROBTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

PROMorgan Stanley Maintains Overweight on BrightSpring Health, Raises Price Target to $80

PROKeybanc Maintains Overweight on BrightSpring Health, Raises Price Target to $80

PROWells Fargo Maintains Overweight on BrightSpring Health, Raises Price Target to $78

PROGuggenheim Initiates Coverage On BrightSpring Health with Buy Rating, Announces Price Target of $81

People Also Watch

People Also Watch

PRO
BTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

PRO
BTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

PRO
Morgan Stanley Maintains Overweight on BrightSpring Health, Raises Price Target to $80

PRO
Keybanc Maintains Overweight on BrightSpring Health, Raises Price Target to $80

PRO
Wells Fargo Maintains Overweight on BrightSpring Health, Raises Price Target to $78

PRO
Guggenheim Initiates Coverage On BrightSpring Health with Buy Rating, Announces Price Target of $81